Combretastatin A-1 bis(phosphate) | 288847-35-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: Combretastatin A-1 bis(phosphate)
• 英文别名: [3-methoxy-2-phosphonooxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate
• CAS: 288847-35-8
• 化学式: C₁₈H₂₂O₁₂P₂
• 分子量: 492.3
• InChiKey: GSOXMQLWUDQTNT-WAYWQWQTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  170
• 氢给体数：
  4
• 氢受体数：
  12

文献信息

• ISO CA-4 AND ANALOGUES THEREOF AS POTENT CYTOTOXIC AGENTS INHIBITING TUBULINE POLYMERIZATION
  申请人：Alami Mouâd

  公开号：US20100129471A1

  公开（公告）日：2010-05-27

  The invention relates to a compound of the formula (I) in which: R 1 , R 2 and R 3 are independently a methoxy group optionally substituted by one or more fluorine atoms; R 4 is a hydrogen atom; R 5 and R 6 are identical and each represent a hydrogen or fluorine atom; A is a cycle selected from the group including aryl and heteroaryl groups, wherein said groups can be substituted.

  这项发明涉及公式（I）的化合物，其中：R1、R2和R3分别是一个甲氧基基团，该基团可以选择性地被一个或多个氟原子取代；R4是一个氢原子；R5和R6相同，每个代表一个氢或氟原子；A是从包括芳基和杂环基团在内的一组环中选择的，其中这些基团可以被取代。
• Compositions and methods for use in tergeting vascular destruction
  申请人：ARIZONA BOARD OF REGENTS

  公开号：EP2289521A2

  公开（公告）日：2011-03-02

  The present invention is directed to compounds of Formula I: wherein X represents cis- or trans- alkenyl group represented by -(CH=CH)1-; each of R1, R2, R3 and R4 is H or Q+, while at least one of R1, R2, R3 and R4 is Q+; and Q+ is a sodium, piperazine, or nicotinamide cation. The invention also relates to pharmaceutical compositions comprising these compounds. The compounds of the invention can be used for the treatment of neoplastic disease.

  本发明涉及式 I 的化合物： 其中X代表顺式或反式烯基，由-(CH=CH)1-代表；R1、R2、R3和R4各自为H或Q+，而R1、R2、R3和R4中至少有一个为Q+；Q+为钠、哌嗪或烟酰胺阳离子。 本发明还涉及包含这些化合物的药物组合物。 本发明的化合物可用于治疗肿瘤性疾病。
• Predictive baseline biomarkers for use of vascular disrupting agents
  申请人：BIONOMICS LIMITED

  公开号：US10520508B2

  公开（公告）日：2019-12-31

  The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.

  本公开涉及可预测患者对血管破坏剂治疗反应的生物标志物铁蛋白和IL-8。特别是，本公开涉及可预测癌症患者对血管破坏剂治疗反应的生物标记物，以及用血管破坏剂治疗癌症患者的方法。
• Predictive biomarkers
  申请人：BIONOMICS LIMITED

  公开号：US10564162B2

  公开（公告）日：2020-02-18

  The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.

  本公开涉及可预测患者对血管破坏剂治疗反应的生物标志物SAP、SHBG、肌红蛋白、MMP-9和SCF。特别是，本公开涉及可预测癌症患者对血管破坏剂治疗反应的生物标记物，以及用血管破坏剂治疗癌症患者的方法。
• METHOD FOR TREATING HEMATOPOIETIC NEOPLASMS
  申请人：Chaplin David

  公开号：US20090192098A1

  公开（公告）日：2009-07-30

  This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.